{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T23:50:53Z","timestamp":1726444253167},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s12098-008-0140-4","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T06:04:34Z","timestamp":1219212274000},"page":"739-743","source":"Crossref","is-referenced-by-count":19,"title":["Current Trends in the Management of Beta Thalassemia"],"prefix":"10.1007","volume":"75","author":[{"given":"A. P.","family":"Dubey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dublish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"key":"140_CR1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1196\/annals.1345.067","volume":"1054","author":"V. Ladis","year":"2005","unstructured":"Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445\u2013450.","journal-title":"Ann N Y Acad Sci"},{"key":"140_CR2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1749-6632.1998.tb10479.x","volume":"850","author":"C.B. Pignatti","year":"1998","unstructured":"Pignatti CB, Rugolotto S, Stefano P, Piga A, Gregorio F, Gamberini M et al. Survival and Disease Complications in Thalassemia Major. Ann N Y Acad Sci 1998; 850: 227\u2013231.","journal-title":"Ann N Y Acad Sci"},{"key":"140_CR3","unstructured":"Guidelines for the Clinical Management of Thalassemia. Thalassemia international federation (TIF) 2007."},{"key":"140_CR4","doi-asserted-by":"crossref","unstructured":"Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassemia. Cochrane Database Syst Rev 2005 19: CD004450.","DOI":"10.1002\/14651858.CD004450.pub2"},{"key":"140_CR5","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2005 Dec 22; [Epub ahead of print]"},{"key":"140_CR6","doi-asserted-by":"crossref","first-page":"872A","DOI":"10.1182\/blood.V104.11.872.872","volume":"104","author":"J. Porter","year":"2004","unstructured":"Porter J, Vichinsky E, Rose C, Piga A, Olivieri N, Gattermann N et al. A Phase II Study with ICL670 (Exjade\u00ae), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload. Blood 2004; 104: 872A\u2013872A.","journal-title":"Blood"},{"key":"140_CR7","doi-asserted-by":"crossref","first-page":"95A","DOI":"10.1182\/blood-2004-09-3652","volume":"106","author":"E. Vichinsky","year":"2005","unstructured":"Vichinsky E, Fischer R, Fung E, Onyekwere O, Porter J, Swerdlow P et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade ((R)) ICL670) is well tolerated and reduces iron. Blood 2005; 106: 95A\u201395A.","journal-title":"Blood"},{"key":"140_CR8","first-page":"121A","volume":"102","author":"A. Piga","year":"2003","unstructured":"Piga A, Galanello R, Cappellini MD, Forni GL, Lupo G, Ford JM et al. Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmaco kinetics (PK) and pharmacodynamics (PD) after 18 months of therapy. Blood 2003; 102: 121A\u2013121A.","journal-title":"Blood"},{"key":"140_CR9","doi-asserted-by":"crossref","first-page":"983A","DOI":"10.1182\/blood.V104.11.3614.3614","volume":"104","author":"A. Piga","year":"2004","unstructured":"Piga A, Galanello R, Foschini ML, Zappu A, Bordone E, Longo F et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade (R): Results of a phase II study in pediatric patients with beta thalassernia major. Blood 2004; 104: 983A\u2013983A.","journal-title":"Blood"},{"key":"140_CR10","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with ta-thalassemia. Blood 2006; 107: 3455\u20133462.","DOI":"10.1182\/blood-2005-08-3430"},{"key":"140_CR11","first-page":"1309","volume":"90","author":"R. Origa","year":"2005","unstructured":"Origa R, Bina P, Agus A, Crobu G, Defraia E, Dess\u00fd C. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90: 1309\u20131314.","journal-title":"Haematologica"},{"key":"140_CR12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","volume":"360","author":"L.J. Anderson","year":"2002","unstructured":"Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta thalassemia. Lancet 2002; 360: 516\u2013520.","journal-title":"Lancet"},{"key":"140_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6823-3-4","volume":"3","author":"A.A. Shamshirsaz","year":"2003","unstructured":"Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M et al. Endocrine complications of thalassemia. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocrine Disorders 2003; 3: 4.","journal-title":"BMC Endocrine Disorders"},{"key":"140_CR14","first-page":"249","volume":"2","author":"V. Sanctis De","year":"2004","unstructured":"De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004; 2: 249\u2013255.","journal-title":"Pediatr Endocrinol Rev"},{"key":"140_CR15","first-page":"540","volume":"82","author":"K.H. Wu","year":"2003","unstructured":"Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 2003; 82: 540\u2013637.","journal-title":"Ann Hematol"},{"key":"140_CR16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2337\/diacare.24.5.850","volume":"24","author":"J. P. S. Chern","year":"2001","unstructured":"Chern J P S, Lin K H, Lu M Y, Lin D T, Lin K S, Chen JD et al. Abnormal Glucose Tolerance in Transfusion-Dependent \u03b2-Thalassemic Patients. Diabetes Care 2001; 24: 850\u2013854.","journal-title":"Diabetes Care"},{"key":"140_CR17","first-page":"478","volume":"77","author":"K. Dmochowski","year":"1993","unstructured":"Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose tolerance in patients with Thalassaemia Major. J Clin Endocrinol Metab 1993; 77: 478\u2013483.","journal-title":"J Clin Endocrinol Metab"},{"key":"140_CR18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(06)70437-6","volume":"6","author":"S. Venti","year":"2006","unstructured":"Venti S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6: 226\u2013233.","journal-title":"Lancet Infect Dis"},{"key":"140_CR19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/adc.57.11.860","volume":"57","author":"J. Tsiantis","year":"1982","unstructured":"Tsiantis J, Xypolita-Tsantili D, Papadakou-Lagoyianni S. Family reactions and their management in a parents group with beta-thalassemia. Arch Dis Child 1982; 57: 860\u2013863.","journal-title":"Arch Dis Child"},{"key":"140_CR20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12098-007-0127-6","volume":"74","author":"D. Shaligram","year":"2007","unstructured":"Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with thalassemia Indian J Pediatr 2007; 74: 727\u2013730.","journal-title":"Indian J Pediatr"},{"key":"140_CR21","first-page":"185","volume":"27","author":"C. Pafumi","year":"2000","unstructured":"Pafumi C, Farina M, Pernicone G et al. At term pregnancies in transfusion-dependent beta-thalassemic women. Clin Exp Obstet Gynecol 2000; 27: 185\u2013187.","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"Suppl3","key":"140_CR22","first-page":"935","volume":"11","author":"N. Skordis","year":"1998","unstructured":"Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 935\u2013943.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl3","key":"140_CR23","first-page":"945","volume":"11","author":"M. Karagiorga-Lagana","year":"1998","unstructured":"Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 945\u2013951.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"140_CR24","first-page":"294","volume":"55","author":"M.J. Cunningham","year":"2004","unstructured":"Cunningham MJ, Macklin EA, Muraca G, Neufeld EJ. Successful pregnancy in thalassemia major women in the Thalassemia Clinical Research Network. Pediatr Res 2004; 55: 294.","journal-title":"Pediatr Res"},{"key":"140_CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2265.2000.00962.x","volume":"53","author":"R. Chatterjee","year":"2000","unstructured":"Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf) 2000; 53: 33\u201342.","journal-title":"Clin Endocrinol"}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-008-0140-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12098-008-0140-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-008-0140-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T20:25:13Z","timestamp":1588883113000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12098-008-0140-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1007\/s12098-008-0140-4","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}